Moneycontrol PRO

Buy Dr. Reddy’s Laboratories; target of Rs 5000: Sharekhan

Sharekhan is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5000 in its research report dated July 28, 2022.

July 31, 2022 / 02:43 PM IST
  • bselive
  • nselive
Todays L/H

Sharekhan's research report on Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories’ (DRL’s) Q1FY23 operating performance reflected high cost pressures that dragged down adjusted operating margins. Results missed estimates and reflected several one-time items. Higher costs and elevated competitive pressures in the US are near-term challenges for DRL, but a strong new product pipeline and growth in base business could help tide over pricing pressures, to certain extent. Expected healthy growth in India business, gradual pick up in the PSAI segment and strong product pipeline in the US including limited competition / FTF products, are key positives.


We retain our Buy recommendation on the stock with a revised PT of Rs 5,000.

For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Dr. Reddy's Laboratories - 290722 - khan

Broker Research
first published: Jul 31, 2022 02:39 pm
ISO 27001 - BSI Assurance Mark